<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401813</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310C101</org_study_id>
    <nct_id>NCT04401813</nct_id>
  </id_info>
  <brief_title>Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-label, Single-arm, Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with
      sintilimab in patients with advanced hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, approximately 18 to 47 patients who have previously received sorafenib,
      lenvatinib, or oxaliplatin-containing chemotherapy . After determining the dose of IBI310,
      the study will enter the expansion phase
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event</measure>
    <time_frame>21-42days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the objective response rate of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma</measure>
    <time_frame>21-42days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the ORR of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma (researched by the investigator according to RECIST V1.1).</measure>
    <time_frame>1years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>IBI310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308 200mg</intervention_name>
    <description>Received IBI310 combined with sintilizumab 200mg</description>
    <arm_group_label>IBI310</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria：

          1. Locally advanced or metastatic hepatocellular carcinoma, confirmed by
             histology/cytology.

          2. Disease progression after surgery and / or local treatment.

          3. Previous standard systemic treatments for advanced hepatocellular carcinoma have
             failed or developed intolerable toxicity.

        exclusion criteria：

          1. Histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid
             hepatocellular carcinoma, cholangiocarcinoma and other components.

          2. Have a history of hepatic encephalopathy, or have a history of liver transplantation.

          3. Diffuse liver cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lian zhou</last_name>
      <phone>021-64041990</phone>
      <email>zhou.jian@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

